Pass the CBIC Infection Control CIC Questions and answers with CertsForce

In quality improvement, a baseline measurement is collected before implementing changes so the team can compare performance over time and determine whether interventions produced improvement. Creating the baseline after changes are implemented defeats the purpose of baseline data because it removes the “pre-intervention” reference point needed to evaluate impact and sustainment. Quality improvement measurement guidance emphasizes capturing a baseline and then continuing measurement at regular intervals to judge the effect of an intervention.

The other activities listed are appropriate for standardizing disinfection and sterilization practices. Direct observation (A) is a common process-assessment method to identify gaps between policy and actual practice. Including central sterile/central supply and OR leaders (B) supports multidisciplinary engagement and ensures changes are operationally feasible where reprocessing occurs. Performing a literature and guidance review (C) helps align local practice with authoritative recommendations (e.g., CDC disinfection/sterilization guidance and monitoring expectations).

The scenario involves an infection preventionist (IP) assisting pharmacists in addressing medication contamination at the hospital’s compounding pharmacy, with a focus on the medication recall process. The IP’s role is to apply infection control expertise to mitigate risks, guided by the Certification Board of Infection Control and Epidemiology (CBIC) principles and best practices. The recall process requires a systematic approach to identify, contain, and resolve the issue, and the “first” or most critical step must be determined. Let’s evaluate each option:

A. Have laboratory culture all medication: Culturing all medication to confirm contamination is a valuable step to identify affected batches and guide the recall. However, this is a resource-intensive process that depends on first understanding the scope and source of the problem. Without identifying the potential source of contamination, culturing all medication could be inefficient and delay the recall. This step is important but secondary to initial investigation.

B. Inspect for safe injection practices: Inspecting for safe injection practices (e.g., single-use vials, proper hand hygiene, sterile technique) is a critical infection control measure, especially in compounding pharmacies where contamination often arises from procedural errors (e.g., reuse of syringes, improper cleaning). While this is a proactive step to prevent future contamination, it addresses ongoing practices rather than the immediate recall process for the current contamination event. It is a complementary action but not the first priority.

C. Identify the potential source of contamination: Identifying the potential source of contamination is the foundational step in the recall process. This involves investigating the compounding environment (e.g., water quality, equipment, personnel practices), raw materials, and production processes to pinpoint where the contamination occurred (e.g., bacterial ingress, cross-contamination). The CBIC emphasizes root cause analysis as a key infection prevention strategy, enabling targeted recalls, corrective actions, and prevention of recurrence. This step is essential before culturing, inspecting, or notifying patients, making it the IP’s primary responsibility in this context.

D. Inform all discharged patients of potential medication contamination: Notifying patients is a critical step to ensure public safety and allow for medical follow-up if they received contaminated medication. However, this action requires prior identification of the contaminated batches and their distribution, which depends on determining the source and confirming the extent of the issue. Premature notification without evidence could cause unnecessary alarm and is not the first step in the recall process.

The best answer is C, as identifying the potential source of contamination is the initial and most critical step in the medication recall process. This allows the IP to collaborate with pharmacists to trace the contamination, define the affected products, and guide subsequent actions (e.g., culturing, inspections, notifications). This aligns with CBIC’s focus on systematic investigation and risk mitigation in healthcare-associated infection events.

CBIC Infection Prevention and Control (IPC) Core Competency Model (updated 2023), Domain III: Prevention and Control of Infectious Diseases, which includes identifying sources of contamination in healthcare settings.

CBIC Examination Content Outline, Domain V: Management and Communication, which emphasizes root cause analysis during outbreak investigations.

CDC Guidelines for Safe Medication Compounding (2022), which recommend identifying contamination sources as the first step in a recall process.

The Certification Study Guide (6th edition) emphasizes that device-associated infection rates must be calculated using time-at-risk denominators to accurately reflect patient exposure. For CLABSI surveillance, the most appropriate denominator is central line days, defined as the total number of days patients have one or more central lines in place during the surveillance period.

Using central line days accounts for both the presence and duration of exposure, which is critical for risk adjustment. The longer a central line remains in place, the greater the opportunity for microbial entry and bloodstream infection. This denominator allows for valid trend analysis over time and meaningful benchmarking with national surveillance systems that use standardized definitions and denominators.

The other options are incorrect because they fail to measure exposure accurately. Total ICU patients and total patients with central lines do not account for how long the device was present. Counting only patients who developed infections incorrectly places outcomes in the denominator, which invalidates rate calculations.

The study guide reinforces that numerators represent infection events, while denominators represent populations or time at risk. For CLABSI, the standard rate is expressed as infections per 1,000 central line days, a core concept frequently tested on the CIC exam.

Accurate denominator selection ensures valid surveillance, supports quality improvement efforts, and enables comparison with national benchmarks—making central line days the correct and most appropriate choice.

The correct answer is A, "Pregnant persons," as they should be excluded from receiving the live attenuated influenza virus (LAIV) vaccine. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which align with recommendations from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), the LAIV, commonly known as the nasal spray flu vaccine, contains a live attenuated form of the influenza virus. This vaccine is contraindicated in pregnant individuals due to the theoretical risk of the attenuated virus replicating and potentially harming the fetus, despite limited evidence of adverse outcomes (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents). Pregnant persons are instead recommended to receive the inactivated influenza vaccine (IIV), which is considered safe during pregnancy.

Option B (healthy persons aged 2 to 49) is incorrect because this group is generally eligible to receive LAIV, provided they have no other contraindications, as the vaccine is approved for healthy, non-pregnant individuals in this age range (CDC Immunization Schedules, 2024). Option C (persons with allergies to chicken feathers) is not a contraindication for LAIV; the vaccine is produced in eggs, and while egg allergy was historically a concern, current guidelines indicate that LAIV can be administered to persons with egg allergies if they can tolerate egg in their diet, with precautions managed by healthcare providers. Option D (persons simultaneously receiving an inactivated vaccine) is also incorrect, as LAIV can be co-administered with inactivated vaccines without issue, according to ACIP recommendations, as there is no significant interference between the two vaccine types.

The exclusion of pregnant persons reflects CBIC’s emphasis on tailoring infection prevention strategies, including vaccination programs, to protect vulnerable populations while minimizing risks (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 - Collaborate with organizational leaders). This decision is based on precautionary principles outlined in CDC and ACIP guidelines to ensure maternal and fetal safety (CDC Prevention and Control of Seasonal Influenza with Vaccines, 2023).

The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies Neisseria meningitidis as a highly transmissible organism spread through respiratory droplets and direct contact with oral secretions. Healthcare personnel who have unprotected, close exposure—such as mouth-to-mouth resuscitation—to a patient with meningococcal meningitis are considered high-risk contacts.

In this scenario, the nurse had direct exposure to respiratory secretions during CPR, which constitutes a significant risk for transmission. The Study Guide emphasizes that postexposure chemoprophylaxis is indicated as soon as possible, ideally within 24 hours of exposure, to prevent invasive meningococcal disease. Recommended prophylactic agents include rifampin, ciprofloxacin, or ceftriaxone, depending on contraindications and institutional protocols.

Option A is incorrect because chlorhexidine oral rinse does not eliminate systemic infection risk. Option B is inappropriate because quarantine is not required for exposed healthcare workers who receive appropriate prophylaxis. Option D is insufficient, as monitoring alone does not adequately reduce the risk of developing disease following high-risk exposure.

Rapid initiation of chemoprophylaxis is a critical infection prevention intervention and a high-yield CIC® exam concept. Early action protects the exposed healthcare worker and prevents secondary transmission within the healthcare setting.

When a positive biological indicator (BI) is detected, the immediate response is to retest the sterilizer using another BI to confirm results. This helps distinguish between a true sterilization failure and a defective BI.

The CBIC Study Guide advises:

“If there is no indication of abnormalities, then the sterilizer should be tested again in three consecutive cycles using paired biological indicators from different manufacturers.”

Immediate recall is reserved for implant loads or confirmed sterilization failure.

Incorrect responses:

A. Check employee technique may be appropriate later but not as a first step.

B. Informing risk manager or C. Notifying patients occurs only after confirmation of failure.

Measles is a highly contagious airborne disease, and the best immediate action in an outpatient clinic without an Airborne Infection Isolation Room (AIIR) is to mask the patient and isolate them in a private room with the door closed.

Why the Other Options Are Incorrect?

A. Patient should be sent home – While home isolation may be necessary, sending the patient home without proper precautions increases exposure risk.

B. Staff should don a respirator, gown, and face shield – While N95 respirators are necessary for staff, this does not address patient containment.

C. Patient should be offered the MMR vaccine – The vaccine does not treat active measles infection and should be given only as post-exposure prophylaxis to susceptible contacts.

CBIC Infection Control Reference

Measles cases in outpatient settings require immediate airborne precautions to prevent transmission​.

The Certification Study Guide (6th edition) emphasizes that when a specific product lot is suspected or confirmed to be contaminated, the first priority is containment and traceability. The infection preventionist must promptly identify where the implicated lot is located within the facility so it can be removed from use, quarantined, and managed according to recall or manufacturer instructions. This step prevents further patient exposure and preserves the ability to conduct an accurate risk assessment.

Locating the affected dressings allows the facility to determine how widely the product has been distributed, whether it is still in use, and which clinical areas may be affected. This information is essential before taking additional actions such as patient notification or broad product removal. The study guide stresses that responses must be proportionate and evidence-based, avoiding unnecessary disruption or alarm.

The other options represent actions that may be considered later, depending on findings. Removing all dressings from the same manufacturer is overly broad when only one lot is implicated. Notifying discharged patients is premature unless patient exposure and risk have been confirmed. Purchasing from a different manufacturer does not address the immediate need to control and investigate the current issue.

CIC exam questions often focus on sequencing of actions during product contamination events. Correctly identifying and isolating the affected product lot is the foundational step that enables safe, effective follow-up and regulatory compliance.

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that when a potential cluster of infections is identified, the first priority is situational awareness. Before implementing control measures or advanced laboratory analysis, the infection preventionist must determine whether the cases are epidemiologically linked. Identifying the location of the patients—such as whether they are on the same unit, service, or clinic—is the essential first step in assessing the likelihood of transmission or a common source.

Option C is correct because determining patient location allows the IP to evaluate spatial and temporal relationships, which form the foundation of outbreak investigation. If the patients are colocated, this may indicate shared staff, equipment, or environmental exposure, guiding immediate and targeted interventions.

Cohorting patients (Option A) is premature without confirming proximity or transmission risk. Monitoring hand hygiene (Option B) is an important control measure but should follow confirmation of potential spread or shared risk factors. Pulsed-field gel electrophoresis (Option D) is an advanced molecular typing method and is never an initial step; it is reserved for later stages when epidemiologic evidence suggests related cases.

For the CIC® exam, this question tests understanding of outbreak investigation sequencing. The Study Guide consistently reinforces that defining who, where, and when comes before interventions or laboratory typing, making determination of patient location the correct first action.

The Certification Study Guide (6th edition) emphasizes that documentation of cleaning, disinfection, and sterilization processes is a fundamental requirement for regulatory compliance and patient safety assurance. Accurate and complete documentation demonstrates that reprocessing activities are performed according to established policies, manufacturer instructions for use (IFUs), and evidence-based standards. This documentation is essential for meeting expectations set by regulatory agencies, accrediting bodies, and internal quality assurance programs.

Documentation provides verifiable proof that critical steps—such as cleaning, monitoring of sterilization parameters, load release, and equipment maintenance—have been performed correctly. In the event of a healthcare-associated infection investigation, recall, or survey, records serve as objective evidence that proper reprocessing practices were followed. The study guide highlights that “if it is not documented, it is considered not done”, a principle commonly tested on the CIC exam.

The other options reflect secondary or indirect benefits but do not represent the primary reason for documentation. Cost reduction is not the intent of reprocessing records. While Spaulding classification informs how items should be reprocessed, documentation alone does not ensure compliance with that framework. Ensuring processes occur regularly is an operational issue rather than a documentation purpose.

CIC exam questions frequently reinforce that documentation supports accountability, traceability, regulatory compliance, and accreditation readiness, making compliance with policies, regulations, and standards the best answer.